ReviewElectronic physician2016
A Review of the Clinical Implications of Breast Cancer Biology.
Review in Electronic physician, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Frequency Survey of Brain Metastases and Its Associated Factors Among Iranian Women with Breast Cancer: A Cross-sectional Study in Tehran City.Galen medical journal · 2024Article
- Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells.International journal of molecular sciences · 2023Review
- Cyanidin 3-glycoside induced apoptosis in MCF-7 breast cancer cell line.Archives of medical science : AMS · 2023Article
- Cancer Progression Is not Different in Mice of Different Gender Inoculated With Cells of the Triple-Negative 4T1 Breast Cancer Model.World journal of oncology · 2022Article
- Recent applications of cell-penetrating peptide guidance of nanosystems in breast and prostate cancer.Oncology letters · 2022Review
- The association between fat mass and obesity-associated (FTO) genotype and serum vitamin D level in breast cancer patients.Journal of cellular and molecular medicine · 2021Article
- The effectiveness of a WeChat-based multimodal nursing program for women with breast cancer: A randomized controlled trial protocol.Medicine · 2020Article
- miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells.Journal of cellular and molecular medicine · 2020Article
- Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials.Cancers · 2019Review
- Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.Experimental and therapeutic medicine · 2018Review
- ZIC1 acts a tumor suppressor in breast cancer by targeting survivin.International journal of oncology · 2018Article
- Association of increased primary breast tumorOncotarget · 2018Article
- Article
- Expression of Tim-3 in breast cancer tissue promotes tumor progression.International journal of clinical and experimental pathology · 2018Article
- Review
- Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017Article
- Relationship among mammographic findings with histopathologic type of breast cancer and human epidermal growth factor receptor 2 (HER2) in young women.Electronic physician · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistologically similar tumors may have different prognoses and responses to treatment. These differences are due to molecular differences. Hence, in this review, the biological interaction of breast cancer in several different areas is discussed. In addition, the performance and clinical application of the most widely-recognized biomarkers, metastasis, and recurrences from a biological perspective and current global advances in these areas are addressed.
objectiveThis review provides the performance and clinical application of the most widely-recognized biomarkers, metastasis, and recurrences from the biological perspective and current global advances in these areas.
methodsPubMed, Scopus, and Google Scholar were searched comprehensively with combinations of the following keywords: "breast cancer," "biological markers," and "clinical." The definition of breast cancer, diagnostic methods, biological markers, and available treatment approaches were extracted from the literature.
resultsEstrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), and Ki-67 are the most well-known biological markers that have important roles in prognosis and response to therapeutic methods. Some studies showed the response of ER-positive and PR-negative tumors to anti-estrogenic treatment to be lower than ER-positive and PR-positive tumors. Patients with high expression of HER-2 and Ki-67 had a poor prognosis. In addition, recent investigations indicated the roles of new biomarkers, such as VEGF, IGF, P53 and P21, which are associated with many factors, such as age, race, and histological features.
conclusionThe objective of scientists, from establishing a relationship between cancer biology infrastructures with clinical manifestations, is to find new ways of prevention and progression inhibition and then possible introduction of less dangerous and better treatments to resolve this dilemma of human society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.